Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor-Reference-Cited by-同舟云学术

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

Published:2023-04-26 Issue:6 Volume:43 Page:720-725
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Karimi Leena¹,Alves Carla L.¹,Terp Mikkel G.¹,Tuttolomondo Martina¹,Portman Neil²³,Ehmsen Sidse¹⁴,Johansen Lene E.¹,Bak Martin⁵,Lim Elgene²³,Ditzel Henrik J.¹⁴⁶^ORCID

Affiliation:

1. Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

2. Garvan Institute of Medical Research Darlinghurst Sydney New South Wales Australia

3. St. Vincent's Clinical School, Faculty of Medicine University of New South Wales Sydney Sydney New South Wales Australia

4. Department of Oncology Institute of Clinical Research Odense University Hospital Odense Denmark

5. Department of Pathology Sydvestjysk Sygehus Esbjerg Denmark

6. Academy of Geriatric Cancer Research (AgeCare) Odense University Hospital Odense Denmark

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12425

Reference9 articles.

1. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.

2. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

3. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

4. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

5. Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project;JCO Precision Oncology;2024-04